IDEAYA Biosciences IDYA 深 滬
交易中 01-29 11:14:55 美东时间
33.085
-0.565
-1.68%
華盛通- 最 高34.02
- 今 開33.39
- 成交量 9.59万股
- 最 低 32.97
- 昨 收 33.65
- 總市值 29.00亿
- 52周最高 39.28
- 市盈率 靜 --
- 換手率 0.11%
- 52周最低 13.45
- 委 比 82.18%
- 總股本 8766.64万
- 歷史最高 47.735
- 量 比 0.48
- 振 幅 3.12%
- 歷史最低 2.95
- 每 手 1
- 風險率 6.11%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 奈飞绩后遭13家大行下调目标价；齐昂银行、美国合众银行获多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从9美元升至50美元；韦德布什：维持Ardelyx, Inc."跑赢大市"评级，目标价从16美元升至19美元
01-22 15:09
RBC Capital Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $45
RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target from $41 to $45.
01-21 22:48
IDEAYA updates precision oncology strategy at JPM 2026
IDEAYA Biosciences ( ($IDYA) ) has provided an update. On January 12, 2026, IDE...
01-12 19:30
IDEAYA sets 2026 objectives to advance registrational trials
IDEAYA Biosciences ( ($IDYA) ) has provided an announcement. On January 11, 202...
01-12 19:29
美股大行评级 | 拼多多、小鹏获Freedom上调目标价；多家大行首予Wealthfront"超配"评级，目标价最高23美元
今日重点评级关注：HC Wainwright & Co.：维持MetaVia Inc."买入"评级，目标价从12美元升至40美元；Canaccord Genuity：维持GH Research"买入"评级，目标价从35美元升至39美元
01-07 17:25
Truist Securities Maintains Buy on IDEAYA Biosciences, Raises Price Target to $60
Truist Securities analyst Gregory Renza maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and raises the price target from $59 to $60.
01-06 23:13
IDEAYA CEO to Outline Cancer Drug Pipeline at Major JPMorgan Conference
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 44th Annual J.P. Morgan Healthcare
01-05 19:06
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 5, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targete...
01-05 19:00
GlaxoSmithKline Ends Collaboration with IDEAYA Biosciences
IDEAYA Biosciences ( ($IDYA) ) has shared an update. On December 4, 2025, Glaxo...
2025-12-06 05:49
On December 4, 2025 GSK Terminated Collaboration With IDEAYA Biosciences; GSK Will Transfer The Werner Helicase And Pol Theta Clinical Programs To The Co In Accordance With The Applicable Provisions Of The Agreement; IDEAYA Biosciences Will Evaluate Its Strategic Options For These Two Programs In 2026, And The Update Does Not Change Its Expectation Of Cash Runway Into 2030
On December 4, 2025, GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) ("GSK") communicated to IDEAYA Biosciences, Inc. (the "Company") its election to terminate the Collaboration, Option and License Agreement, dated
2025-12-06 05:26
